Blueprint Medicines Corporation (BPMC)
Market Cap | 2.72B |
Revenue (ttm) | 204.04M |
Net Income (ttm) | -557.52M |
Shares Out | 59.98M |
EPS (ttm) | -9.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 127,140 |
Open | 44.66 |
Previous Close | 44.29 |
Day's Range | 44.32 - 45.74 |
52-Week Range | 37.82 - 79.40 |
Beta | 0.69 |
Analysts | Buy |
Price Target | 70.26 (+54.54%) |
Earnings Date | May 2, 2023 |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRE... [Read more]
Financial Performance
In 2022, BPMC's revenue was $204.04 million, an increase of 13.30% compared to the previous year's $180.08 million. Losses were -$557.52 million, -13.44% less than in 2021.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $70.26, which is an increase of 54.54% from the latest price.
News

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on ...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , March 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunother...

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
-- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with improvements shown across all individual symptoms -- -- AYVAK...

Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib)...

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
-- Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues -- -- Continued progress toward regulatory approvals of AYVAKIT/A...

Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.

Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
CAMBRIDGE, Mass. , Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on Februa...

Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
CAMBRIDGE, Mass. , Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
-- Significant scientific and clinical presence, including 10 presentations, underscores breadth and depth of SM leadership -- -- Blueprint Medicines to host investor conference call and webcast on Mo...

Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable...

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag
The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass. , Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S...

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D.

Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
-- Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million -- -- Positioned for significant near-...

Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass. , Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announc...

Blueprint Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Nov. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera...

Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting
CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of abstracts highlighting long-term clinical outcomes and impact on overal...

Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.16% and 51.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
-- On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023 -- -- Reports updated data from the SYMPHO...